These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22844498)

  • 1. Platelets induce apoptosis during sepsis in a contact-dependent manner that is inhibited by GPIIb/IIIa blockade.
    Sharron M; Hoptay CE; Wiles AA; Garvin LM; Geha M; Benton AS; Nagaraju K; Freishtat RJ
    PLoS One; 2012; 7(7):e41549. PubMed ID: 22844498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
    Nakada MT; Sassoli PM; Tam SH; Nedelman MA; Jordan RE; Kereiakes DJ
    J Thromb Thrombolysis; 2002 Aug; 14(1):15-24. PubMed ID: 12652146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sepsis alters the megakaryocyte-platelet transcriptional axis resulting in granzyme B-mediated lymphotoxicity.
    Freishtat RJ; Natale J; Benton AS; Cohen J; Sharron M; Wiles AA; Ngor WM; Mojgani B; Bradbury M; Degnan A; Sachdeva R; Debiase LM; Ghimbovschi S; Chow M; Bunag C; Kristosturyan E; Hoffman EP
    Am J Respir Crit Care Med; 2009 Mar; 179(6):467-73. PubMed ID: 19136373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A; Musumeci G; D'Angelillo A; Rossini R; Zoccai GB; Messina S; Coscioni E; Romano S; Romano MF
    Curr Drug Metab; 2016; 17(2):194-203. PubMed ID: 26652157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
    Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothermia-induced platelet aggregation: no effect of aprotinin (trasylol) but inhibition by eptifibatide (integrilin).
    Straub A; Azevedo R; Beierlein W; Wendel HP; Scheule AM; Ziemer G
    Thorac Cardiovasc Surg; 2005 Apr; 53(2):80-4. PubMed ID: 15786005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
    Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
    Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro.
    Scholz T; Zhao L; Temmler U; Bath P; Heptinstall S; Lösche W
    Platelets; 2002 Nov; 13(7):401-6. PubMed ID: 12487787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
    Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
    Thorac Cardiovasc Surg; 2006 Apr; 54(3):162-7. PubMed ID: 16639676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ; Jordan RE; Mascelli MA
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M
    Acta Pol Pharm; 2009; 66(3):235-42. PubMed ID: 19645323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
    Mousa SA; Bozarth JM; Forsythe MS; Slee A
    Cardiovasc Res; 2000 Sep; 47(4):819-26. PubMed ID: 10974231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of eptifibatide.
    Phillips DR; Scarborough RM
    Am J Cardiol; 1997 Aug; 80(4A):11B-20B. PubMed ID: 9291241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
    Moser M; Bertram U; Peter K; Bode C; Ruef J
    J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.
    Li YF; Spencer FA; Becker RC
    Am Heart J; 2002 Apr; 143(4):725-32. PubMed ID: 11923812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.
    Schwarz M; Meade G; Stoll P; Ylanne J; Bassler N; Chen YC; Hagemeyer CE; Ahrens I; Moran N; Kenny D; Fitzgerald D; Bode C; Peter K
    Circ Res; 2006 Jul; 99(1):25-33. PubMed ID: 16778135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-kappaB activation of human neutrophils.
    Salanova B; Choi M; Rolle S; Wellner M; Luft FC; Kettritz R
    J Biol Chem; 2007 Sep; 282(38):27960-9. PubMed ID: 17644514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.